Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Vasodilator Agents

Lipid Regulating Agents

Hematinics

Vitamins

Bevacizumab

Angiogenesis Inhibitors

Sunitinib

Sorafenib

Imetelstat

Motesanib diphosphate

Trebananib

Niacinamide

Niacin

Nicotinic Acids

Antineoplastic Agents, Immunological

Growth Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Trace Elements

Nicotinamide

Nicotinic Acid

Vitamin B3

Folate

Vitamin B9

3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)

3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)

3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)

3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)

10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)

3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)

10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)

10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)

AMG 706

AMG 386

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 386 when used in combination with AMG 706, bevacizumab, sorafenib, or sunitinib and that at least one dose level from each combination will be safe and well tolerated.

AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.	NCT00861419	Advanced Solid ...	Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386	18 Years -	Amgen
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.	NCT00861419	Advanced Solid ...	Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386	18 Years -	Amgen

Spots Global Cancer Trial Database for peptibody

Every month we try and update this database with for peptibody cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for peptibody

Every month we try and update this database with for peptibody cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for peptibody cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.